Fast AZ Tagrisso Approval Springboard For Clovis?

Prescription Drug User Fee Act (PDUFA) action dates have become meaningless at the FDA's Office of Hematology and Oncology Products, which has almost consistently for the past year or two leaped ahead of those timelines and approved cancer medicines well ahead of schedule – the most recent being AstraZeneca PLC's lung cancer drug Tagrisso (osimertinib).